Braftovi Approval History
FDA Approved: Yes (First approved June 27, 2018)
Brand name: Braftovi
Generic name: encorafenib
Dosage form: Capsules
Company: Array BioPharma Inc.
Treatment for: Melanoma, Metastatic
Braftovi (encorafenib) is a kinase inhibitor indicated, in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test.
Development History and FDA Approval Process for Braftovi
|Jun 27, 2018||Array BioPharma Announces FDA Approval of Braftovi (encorafenib) in Combination with Mektovi (binimetinib) for Unresectable or Metastatic Melanoma with BRAF Mutations|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.